Population
Patients with ventricular arrhythmias
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support propafenone for nonsustained ventricular arrhythmias; leaves open consistent efficacy in sustained cases.
Key Points
- Review the pharmacological mechanisms, electrophysiological properties, and clinical efficacy of propafenone hydrochloride for the management of ventricular arrhythmias.
- Evaluated the pharmacokinetics and electrophysiological properties of propafenone hydrochloride as an oral sodium-channel blocker.
- Assessed comparative clinical actions against related antiarrhythmic agents, including flecainide and encainide.
- Propafenone suppresses nonsustained ventricular arrhythmias effectively, but exhibits less consistent efficacy in sustained ventricular arrhythmias.
- The compound functions primarily as a cardiac sodium-channel blocker while demonstrating clinically relevant beta-adrenergic receptor antagonist properties.
Structured PICO
P
Population
Patients with ventricular arrhythmias
I
Intervention
Propafenone hydrochloride (oral)
Propafenone is an oral antiarrhythmic agent that acts as a sodium-channel blocker with beta-adrenergic antagonist properties, effective for suppressing nonsustained ventricular arrhythmias.
Cite This Study
Oates et al. (1990) studied this question.